The analysis, derived from the REZOLVE-AD study, examined blood and skin samples from 100 participants. Researchers observed that the investigational biologic—a first-in-class agent designed to restore immune balance by targeting the IL-2 receptor complex—prompted significant up-regulation of FOXP3 and IL2RA as early as the second week of treatment. These changes were accompanied by a broader normalization of Th1, Th2, Th17, and JAK-STAT signaling pathways.

Dr. Emma Guttman-Yassky of the Icahn School of Medicine at Mount Sinai noted that these early molecular shifts provide a critical link to clinical outcomes at Week 16. Unlike placebo recipients, patients treated with 24 µg/kg of the drug exhibited a consistent reduction in disease severity, with early serum biomarker changes—such as increased IL-10 and TGFβ1 expression—serving as reliable indicators of later EASI score improvements. These results bolster the case for the drug’s potential to address the underlying immune dysfunction that leaves over half of adult dermatitis patients inadequately controlled by existing therapies.